CUFinder

Zilu Zhang

Zilu Zhang

Harvard University

H-index: 15

North America-United States

Contact Zilu Zhang

About Zilu Zhang

Zilu Zhang, With an exceptional h-index of 15 and a recent h-index of 15 (since 2020), a distinguished researcher at Harvard University, specializes in the field of Big data, Clinical Trial Design, HEOR, Causal Inference.

His recent articles reflect a diverse array of research interests and contributions to the field:

Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor‐naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single‐arm study

P785: SIX-MONTH CROVALIMAB EXTENSION IN THE PHASE 3 COMMODORE 3 STUDY: UPDATED EFFICACY AND SAFETY RESULTS IN COMPLEMENT INHIBITOR-NAIVE PATIENTS (PTS) WITH PAROXYSMAL …

S181: THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO …

Results from the first phase 3 Crovalimab (C5 inhibitor) study (COMMODORE 3): efficacy and safety in complement inhibitor-naive patients with paroxysmal nocturnal …

111P Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours

Comparative effectiveness and safety of 32 pharmacological interventions recommended by guidelines for coronavirus disease 2019: a systematic review and network meta-analysis …

Survival associated with mutations in SWI/SNF chromatin remodeling complex genes.

Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated …

Zilu Zhang Information

University

Position

Harvard Medical School and Dana Farber Cancer Institute

Citations(all)

1006

Citations(since 2020)

828

Cited By

471

hIndex(all)

15

hIndex(since 2020)

15

i10Index(all)

18

i10Index(since 2020)

17

Email

University Profile Page

Google Scholar

Zilu Zhang Skills & Research Interests

Big data

Clinical Trial Design

HEOR

Causal Inference

Top articles of Zilu Zhang

Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor‐naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single‐arm study

American Journal of Hematology

2023/9

Hui Liu
Hui Liu

H-Index: 21

Chuan He
Chuan He

H-Index: 19

Zilu Zhang
Zilu Zhang

H-Index: 10

Rong Fu
Rong Fu

H-Index: 9

P785: SIX-MONTH CROVALIMAB EXTENSION IN THE PHASE 3 COMMODORE 3 STUDY: UPDATED EFFICACY AND SAFETY RESULTS IN COMPLEMENT INHIBITOR-NAIVE PATIENTS (PTS) WITH PAROXYSMAL …

HemaSphere

2023/8/1

Hui Liu
Hui Liu

H-Index: 21

Chuan He
Chuan He

H-Index: 19

Zilu Zhang
Zilu Zhang

H-Index: 10

Rong Fu
Rong Fu

H-Index: 9

S181: THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO …

HemaSphere

2023/8/1

Richard Kelly
Richard Kelly

H-Index: 16

Brittany Gentile
Brittany Gentile

H-Index: 24

Zilu Zhang
Zilu Zhang

H-Index: 10

Bing Han
Bing Han

H-Index: 16

Results from the first phase 3 Crovalimab (C5 inhibitor) study (COMMODORE 3): efficacy and safety in complement inhibitor-naive patients with paroxysmal nocturnal …

Blood

2022/11/15

Hui Liu
Hui Liu

H-Index: 21

Chuan He
Chuan He

H-Index: 19

Yuchen Zhang
Yuchen Zhang

H-Index: 15

Zilu Zhang
Zilu Zhang

H-Index: 10

Rong Fu
Rong Fu

H-Index: 9

111P Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours

Annals of Oncology

2022/4/1

J Li
J Li

H-Index: 9

Z Zhang
Z Zhang

H-Index: 37

Comparative effectiveness and safety of 32 pharmacological interventions recommended by guidelines for coronavirus disease 2019: a systematic review and network meta-analysis …

2021/8/20

Survival associated with mutations in SWI/SNF chromatin remodeling complex genes.

2020/5/20

Zilu Zhang
Zilu Zhang

H-Index: 10

Deborah Schrag
Deborah Schrag

H-Index: 74

Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated …

2020/5/20

David Cunningham
David Cunningham

H-Index: 6

Zilu Zhang
Zilu Zhang

H-Index: 10

gfoRmula: An R package for estimating the effects of sustained treatment strategies via the parametric g-formula

Patterns

2020/4

Victoria Lin
Victoria Lin

H-Index: 4

Zilu Zhang
Zilu Zhang

H-Index: 10

Miguel Hernan
Miguel Hernan

H-Index: 82

Developing a standardized and reusable method to link distributed health plan databases to the National Death Index: Methods development study protocol

JMIR research protocols

2020/11/2

Ryan Carnahan
Ryan Carnahan

H-Index: 25

Katelyn King
Katelyn King

H-Index: 3

Andrew B Petrone
Andrew B Petrone

H-Index: 14

Jessica Young
Jessica Young

H-Index: 2

Consequences of depletion of susceptibles for hazard ratio estimators based on propensity scores

Epidemiology

2020/11/1

Zilu Zhang
Zilu Zhang

H-Index: 10

Richard Wyss
Richard Wyss

H-Index: 12

Humanism and professionalism training for pediatric hematology‐oncology fellows: Results of a multicenter randomized trial

Pediatric Blood & Cancer

2020/11

Zilu Zhang
Zilu Zhang

H-Index: 10

Distributed regression analysis application in large distributed data networks: analysis of precision and operational performance

JMIR Medical Informatics

2020/6/4

Zilu Zhang
Zilu Zhang

H-Index: 10

Jessica Young
Jessica Young

H-Index: 2

See List of Professors in Zilu Zhang University(Harvard University)

Co-Authors

academic-engine

Useful Links

List of top 50 universities
List of top 100 universities
List of top 500 universities
Find Professors Email
Find Universities Email
CUFinder Academic Engine